Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanzalintinib in Recurrent Or Metastatic Olfactory Neuroblastoma
NCT07527169Phase 2Not yet recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2026
- Primary completion
- Jul 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of zanzalintinib in olfactory neuroblastoma (ONB), sponsored by University of Texas MD Anderson Cancer Center. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
zanzalintinib
03
Conditions
olfactory neuroblastoma (ONB)
Beyond the preview
Go deeper on NCT07527169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07527169.